Nephrology / Hematology / Oncology – New Chemical Entities (NCEs)
Multi-indications / Multi-drug candidates
In addition to these indications (CIA, CRA or CKD) other potential applications for PBI-1402 could include the treatment of anemia in the elderly, anemia from bone marrow stem cell transplants, and anemia caused by the use of zidovudine in HIV patients.
Several NCEs identified by ProMetic’s scientists offer numerous possibilities for additional indications and market segments. Additionally, ProMetic’s drug discovery platform has led to the development of numerous compounds for the treatment of cancer and autoimmune diseases. Compounds such as PBI-1393, PBI-0110, PBI-1737, PBI-1668, and PBI-1522 have all demonstrated very impressive activity in various cancer models and represent real drug candidate potential. Additionally, most of these compounds are orally active and preclinical in vivo results seem to indicate that they could be used in combination with standard treatment protocols, such as lowered dosages of chemotherapy, thus resulting in a reduction of associated side-effects such as anemia and / or neutropenia. PBI-1393 and PBI-0110 are in position to enter clinical trials in 2008 subject to corporate strategy. Furthermore, PBI-1737 has evidenced strong results in several different autoimmune and anti-inflammatory models, including simulations of colitis (Irritable Bowel Syndrome, Crohn’s disease) and Multiple Sclerosis. PBI-1308 is a synthetic compound that has been partnered with Darier for further development in the fields of atopic dermatitis and psoriasis. The continued development of the analogues of PBI-1402, and the NCEs signify a family of candidate therapeutics. The implication is far-reaching.
These compounds represent a complete, well defined platform with the ability to produce high-value drugs. This will allow ProMetic to address unmet medical needs and extremely complex medical conditions associated with certain diseases, for which the market potential is immense.